@JensenHuang “Their value is not fixed at installation: CUDA continuously improves their output; the installed base remains productive well beyond its initial depreciation period;”
Sorry @michaeljburry
Bloomberg just ran a front page piece on the psychedelics industry. A lot of the attention was on $CMPS and potential FDA approval.
The real takeaway just reinforced what's driven my own conviction, much of which @C_Angermayer has written about extensively.
Psilocybin- One dose/8 hours/therapist on standby
It's to envision how that reaches critical mass beyond high-end treatment boutiques.
BPL003- Designed to align with the infrastructure established by Spravato- short clinic time, repeatable workflow, scalable.
Stripping this down to simple TAM and adoption it becomes pretty clear why $ATAI sold down most of its Compass ownership and leaned into this path.
I am a big believer in Psilocybin and its future role in the treatment of mental illness, I am strictly viewing this through the lens of capital allocation.
As a whole this is a very interesting and exciting time to watch the space.
@markpinc I think we turn a major corner soon starting w strong earnings, specs spinoff w external partner, line of sight re memory storage fees
But I have been burned and wrong for a while :)